CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment

References

• Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:1096–1103.
   PubMed Web of Science ®Google Scholar
• Sjöberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973–2009. Blood 2012;119:990–996.
   PubMed Web of Science ®Google Scholar
• Institut National du Cancer (France). Situation du cancer en France en 2011. pp 97–99. Available from: www.e-cancer.fr/expertises-publications-de-l-inca/rapports-et-expertises/sante-publique
   Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362: 875–885.
   PubMed Web of Science ®Google Scholar
• Steidl C, Farinha P, Gascoyn RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 2011;96:186–189.
   PubMed Web of Science ®Google Scholar
• Lau SK, Chu PG, Weiss LM. CD163 a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004;122: 794–801.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301–308.
   PubMed Web of Science ®Google Scholar
• Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52:1913–1919.
   PubMed Web of Science ®Google Scholar
• Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011; 96:269–76.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012;88:292–305.
   PubMed Web of Science ®Google Scholar
• Zaki MA, Wada N, Ikeda J, et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011;459:361–366.
   PubMed Web of Science ®Google Scholar
• Tan KL, Scott DW, Hong F, et al. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012;120:3280–3287.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013;31: 256–262.
   PubMed Web of Science ®Google Scholar
• Deau B, Bachy E, Ribrag V, et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:41–45.
   PubMed Web of Science ®Google Scholar
• Casulo C, Arcila M, Bohn OL, et al. Tumor associated macrophages in relapsed and refractory Hodgkin lymphoma. Leuk Res 2013;37: 1178–1173.
   PubMed Web of Science ®Google Scholar
• Azambuja D, Natkuman Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736–742.
   PubMed Web of Science ®Google Scholar
• Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma. Haematologica 2012;97:1080–1084.
   PubMed Web of Science ®Google Scholar
• Harris JA, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12.
   PubMed Web of Science ®Google Scholar
• Connors JM. Positron emission tomography in the management of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011:317–322.
   Google Scholar
• Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160–1168.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–59.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to International Prognostic Score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–3752.
   PubMed Web of Science ®Google Scholar
• Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 2011;22:910–915.
   PubMed Web of Science ®Google Scholar
• Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma 2014;55:31–37.
   PubMed Web of Science ®Google Scholar
• Ferme C, Cosset JM, Fervers B, et al.; French National Federation of Cancer (FNCLCC). Hodgkin's disease. Br J Cancer 2001;84(Suppl. 2):55–60.
   PubMed Web of Science ®Google Scholar
• Engert A, Dreyling M. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Ann Oncol 2008;19(Suppl. 2):ii65–ii66.
   PubMedGoogle Scholar
• Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3–13.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7: 1630–1636.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523–531.
   Google Scholar
• Monteil J, Mahmoudi N, Leobon S, et al. Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans. Anticancer Res 2009;29:2563–2568.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Casasnovas O, André M, et al. Classical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica 2013;98:1185–1195.
   PubMed Web of Science ®Google Scholar
• Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?Hematology Am Soc Hematol Educ Program 2012:322–327.
   Google Scholar
• Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009;50:1257–1260.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Itti E, et al. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:1876–1881.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?Blood 2012;120:4913–4920.
   PubMed Web of Science ®Google Scholar
• Biggi A, Gallamini A, Chauvie S, et al. International validation study for Interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683–690.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Scott DW, Steidl C. Molecular pathology of Hodgkin's lymphoma: prognostic implications. Hematol Educ 2012; 6:165–174.
   Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29: 1812–1826.
   PubMed Web of Science ®Google Scholar
• Diehl V. Are macrophages the bad gays in Hodgkin lymphoma?Nat Rev Clin Oncol 2010;7:301–302.
   PubMed Web of Science ®Google Scholar
• Blum KA. Upcoming diagnosis and therapeutic developments in classical Hodgkin's lymphoma. Hematology Am Soc Hematol Educ Program 2010:93–100.
   Google Scholar
• Borchmann P, Engert A. Clinical advances in Hodgkin lymphoma. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010:101–107.
   Google Scholar
• Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography on Hodgkin lymphoma treatment outcome is confirmed using the 5-point scale interpretation criteria. Haematologica 2014 Mar 21. [Epub ahead of print]
   Google Scholar
• Oki Y, Chuang H, Chasen B, et al. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 2014;165:112–116.
   PubMed Web of Science ®Google Scholar